CompletedNCT00889915
Comparing newer and established medicines for ADHD
About this title
Read the official source — NCT00889915Medication studyAges 6–17United States
Understand this study
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- DurhamSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateApril 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 228
- Sponsor
- Duke University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT00889915
- Official title
Show the full official title
A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended Release (Adderall XR) in Children and Adolescents With ADHD
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Durham
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Duke University, a university.
Did this study involve medication?
Yes. The study involved medication, including Methylphenidate transdermal system, Lisdexamfetamine dimesylate, Osmotic-release oral system methylphenidate (OROS MPH) and Mixed amphetamine salts extended release.
Who was this study for?
Listed age limits: 6 years to 17 years.
